Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

New York – December 3, 2024 – Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept. Subject to the terms of the agreement, Keros will receive a $200 million upfront cash payment and is eligible to receive development, approval and commercial milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales. Takeda, meanwhile, will obtain an exclusive license to further develop, manufacture and commercialize elritercept worldwide, outside of mainland China, Hong Kong and Macau, and will be responsible for all development, manufacturing and commercialization as of the agreement’s effective date.

Lawyers Alan Tamarelli, Ryan Sansom, Marc Recht, David Burns, Natasha Kaye, Navya Dasari, Amanda Pacheco and Bartholomäus Regenhardt led the Cooley team advising Keros.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.